Oravax Medical 的封面图片
Oravax Medical

Oravax Medical

制药业

Oravax is developing breakthrough technologies for the oral delivery of vaccines.

关注

关于我们

Oravax Medical is developing an oral COVID-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.

网站
https://www.ora-vax.com/
所属行业
制药业
规模
11-50 人
类型
私人持股
创立
2021
领域
Oral Vaccines和Oral Covid-19 Vaccine

相似主页

查看职位